RSV vax for over-60s looms as regulators weigh up candidates
GSK Australia has applied for TGA approval of its RSV vaccine candidate, Arexvy.
The TGA is weighing up Australia’s first potential respiratory syncytial virus vaccine, while the US regulator has given preliminary approval to two vaccine candidates, as the RSV vaccine race tightens.
GSK Australia lodged applied to the TGA for approval of protein-based vaccine Arexvy this year, following positive results from its phase III clinical trial.
